Account Executive

Taysha Gene Therapies and Catalent expand strategic partnership to include future commercial manufacturing support of TSHA-102 gene therapy for Rett Syndrome. 08-03-2026 CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) - Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha's investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha's primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval. Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand. Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products. "As we continue to advance TSHA-102, establishing long-term commercial manufacturing capacity is a critical component of our launch readiness strategy," said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. "Catalent's deep gene therapy expertise and proven commercial manufacturing capabilities make them an ideal partner as we expand our partnership to further strengthen our commercial infrastructure with a reliable, scalable supply framework. With BLA-enabling Process Performance Qualification activities underway, we believe we have established the manufacturing foundation necessary to support the strong demand we expect following the potential launch and commercialization of TSHA-102." "At Catalent, our priority is to support innovators who are redefining what's possible for patients with rare diseases," said David McErlane, Biologics Group President for Catalent. "Our partnership with Taysha brings together deep AAV expertise and a shared commitment to advancing a potential therapy for Rett syndrome - a condition with significant unmet need. We are proud to help enable the development and future supply of therapies that have the potential to make a meaningful difference for patients and their families." This partnership reflects Catalent's continued commitment to supporting innovators across the cell and gene therapy landscape, providing end-to-end solutions from development through commercialization to help bring transformative therapies to patients. About Rett Syndrome Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com. About Catalent Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers' needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102 and Taysha's other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha's research, development and regulatory plans for its product candidates; the potential demand for TSHA-102; and the ability of the agreement between Taysha and Catalent to secure long-term commercial manufacturing capacity and a scalable supply framework for the commercial supply of TSHA-102. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha's business are described in detail in its SEC filings, including in Taysha's Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law. Taysha Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. [email protected] Catalent Media Contact: [email protected]

Banks pay backhanded compliments to private credit. Liz Hoffman Liz's view. The narrative about private credit is familiar by now - it's a garbage heap of bad loans, waiting to ignite. A tiny corrective comes from a strange place: the industry's biggest competitors. Big banks have been busy refinancing loans made by private-credit firms. By putting their own balance sheets and brand names behind these deals, banks are validating the very underwriting they've spent months criticizing for being full of cockroaches. Deutsche Bank is selling $3 billion of fresh debt to refinance a loan that accounting firm Baker Tilly took out just a year ago from Blackstone, Blue Owl, and others. JPMorgan and Morgan Stanley are working on a $4 billion loan to drug manufacturer Catalent that would replace a private-credit facility, with early price talk similarly around two points lower, according to people familiar with the matter. Alera replaced a 2021 private-credit loan with a cheaper one arranged by Goldman Sachs and Bank of Montreal. Banks were always the cheaper option for borrowers; private-credit firms charged a premium for the certainty they offered, which mattered in volatile moments like the weeks after President Donald Trump's "Liberation Day" tariffs when Baker Tilly came knocking. But it's notable that banks are stepping in again: If they believed these borrowers were headed for trouble, they wouldn't be fighting to lend to them at tighter spreads than even a broadly improving credit market would justify. These are bets on healthy companies. Banks are almost certainly cherrypicking. The deals getting refinanced are not, you'll notice, the software companies threatened by AI or the leveraged buyouts sitting on shaky ground. The weakest private-credit loans remain exactly where they started. And the real risk for private lenders is a slow-motion adverse selection: Their safest, most bankable borrowers get taken, leaving them holding the rest. Notable. * Blue Owl earlier this month was hit by $4.7 billion in redemptions as investors get jittery about private credit loans to software companies menaced by AI, Semafor reported. * Blackstone announced in June it had capped withdrawals from its flagship Blackstone Private Credit fund following a surge in withdrawal requests, CNBC reported.

Codis to acquire Catalent's Nottingham facility to create Europe's leading end-to-end spray drying capability. 08-Jul-2026 Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, announced an agreement with Catalent Pharma Solutions to acquire Catalent's facility in Nottingham, UK. The acquisition, expected to close in Q3 of this year subject to customary closing conditions, will add oral solid dose (OSD) development and small-scale manufacturing capabilities and create Europe's leading single partner path for integrated spray dry solutions, from development through clinical supply and commercial intermediates, to final oral dose forms. The Nottingham site brings a highly experienced team and deep scientific expertise in formulation development and clinical supply, successfully delivering development-scale spray drying and OSD solutions for over two decades. Codis is excited to welcome the Nottingham team into the organization. This acquisition will strategically complement Codis' large scale commercial spray drying facility in Haverhill, UK, which is now undergoing significant expansion with a new GEA Pharma-SD(R) type PSD-4 commercial spray dryer scheduled to be validated in 2027. It will also augment Codis' current portfolio of bioavailability enhancement solutions with integrated development, analytical, and clinical and small-scale commercial manufacturing co-located at the site. "This strategic acquisition will further establish Codis as a leading European provider of comprehensive spray dry solutions," said Nicolas Fortin, CEO of Codis. "The close proximity of our Nottingham and Haverhill sites creates a unique advantage. Codis can now offer access to the best scientific expertise with a strong, integrated manufacturing capability within a single organization and quality system." Mr Fortin noted, "Most small-molecule drug candidates suffer from poor solubility, and spray-dried dispersions have become one of the primary approaches to improving bioavailability. Yet one of the greatest development risks remains the transfer from formulation to commercial-scale manufacturing. By bringing formulation development and GMP manufacturing together, we provide the fastest, lowest-risk path to unlocking a molecule's full potential."